Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Chagas disease 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
2 Chagas disease 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
3 Chagas disease 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
4 Epstein-Barr virus infection 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
5 Epstein-Barr virus infection 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
6 Epstein-Barr virus infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
7 Hematopoietic cell lineage 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
8 Hematopoietic cell lineage 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
9 Hematopoietic cell lineage 💬
2件: CD3E, MS4A1 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
10 Human immunodeficiency virus 1 infection 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
11 Human immunodeficiency virus 1 infection 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
12 Human immunodeficiency virus 1 infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
13 Human T-cell leukemia virus 1 infection 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
14 Human T-cell leukemia virus 1 infection 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
15 Human T-cell leukemia virus 1 infection 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
16 Measles 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
17 Measles 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
18 Measles 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
19 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
20 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
21 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
22 Primary immunodeficiency 💬
2件: CD3D, CD3E 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
23 Primary immunodeficiency 💬
2件: CD3D, CD3E 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
24 Primary immunodeficiency 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
25 T cell receptor signaling pathway 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
26 T cell receptor signaling pathway 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
27 T cell receptor signaling pathway 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
28 Th1 and Th2 cell differentiation 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
29 Th1 and Th2 cell differentiation 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
30 Th1 and Th2 cell differentiation 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬
31 Th17 cell differentiation 💬
3件: CD3D, CD3E, CD3G 💬 Otelixizumab 💬 Otelixizumab 1件: 46 💬
32 Th17 cell differentiation 💬
3件: CD3D, CD3E, CD3G 💬 Visilizumab 💬 Visilizumab 2件: 96, 97 💬
33 Th17 cell differentiation 💬
1件: CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab 1件: 49 💬